Ticker brief

BBIO BRIDGEBIO PHARMA INC

Consumer, Non-cyclical · Biotechnology

last close
$77.19
1 day
+3.6%
14 days
+16.5%
mkt cap
$15.1B
signals 14d
26
authors 14d
11
Sentiment — last 14 days
daily mean sentiment, 2026-06-22 → 2026-07-02 · now +0.43 (−1 bearish … +1 bullish)
Who spoke11
authorgradetrader scoresignalsmean sent
@semodoughC-0.7510+0.46
@OzmosiHealthC·4+0.21
@Biotech2k1A-0.033+0.38
@PersimmonTIA-0.322+0.35
@PrismMarketViewC·1+0.45
@Quantumup1C-1.951+0.00
@AlertsAndNewsC+1.521+0.20
@AponiaAnalyticsB+0.891+0.55
@BioStocksC-0.391+0.20
@OpenOutcrierC·1+0.25
@FiercePharmaB+1.391+0.20
Recent signals26of 26 in 14d — receipts included
date (PT)authorsentwhat they saidsince thenreceipt
2026-07-02@semodough+0.40Speculates on BBIO and praises management and pipeline quality.—
2026-07-02@semodough+0.60Says BBIO has superior drug to PFE and increasing doctor tailwinds.—
2026-07-02@OzmosiHealth+0.35Acoramidis associated with early and sustained kidney-protective effects.—
2026-07-02@PersimmonTI+0.35Positive post-hoc analysis differentiation for acoramidis is cited for BBIO.—
2026-07-01@FiercePharma+0.20BridgeBio secured $1B to support launches; analyst says other plans possible.+3.6%
2026-07-01@OpenOutcrier+0.25BridgeBio gets $1B financing from Sixth Street and HCRx for launches.+3.6%
2026-07-01@BioStocks+0.20BBIO raises $1B preferred equity led by Sixth Street and KKR.+3.6%
2026-06-29@Biotech2k1+0.25Watchlist of value levels across sectors, no explicit buy action.+7.2%
2026-06-29@AponiaAnalytics+0.55Phase 3 PROPEL 3 met all key endpoints with NDA planned for Q3 2026.+7.2%
2026-06-29@semodough+0.55Author says safety is better than expected and likely another $4B+ drug for BBIO.+7.2%
2026-06-29@semodough+0.45Piper has Buy rating and $112 PT on BBIO after trial data and NEJM publication.+7.2%
2026-06-29@semodough+0.40BofA maintains Buy and $101 PT on BBIO, citing infigratinib as key growth contributor.+7.2%
2026-06-29@semodough+0.45Morgan Stanley raises BBIO PT to $98 and reiterates Overweight after FDA accepted NDA with priority review.+7.2%
2026-06-29@semodough+0.40BofA rates BBIO Buy with $101 PT after additional PROPEL3 data.+7.2%
2026-06-28@AlertsAndNews+0.20BridgeBio NEJM Phase 3 publication and plans NDA in Q3 2026 with launch anticipated 2027.+9.9%
2026-06-28@semodough+0.65BridgeBio Phase 3 PROPEL 3 data published in NEJM showed statistically significant arm span and AHV benefits.+9.9%
2026-06-28@semodough+0.35BridgeBio announced NEJM publication of Phase 3 PROPEL 3 oral infigratinib trial.+9.9%
2026-06-28@OzmosiHealth+0.20BridgeBio announces NEJM publication of Phase 3 PROPEL 3 trial.+9.9%
2026-06-27@PersimmonTI+0.35Calls NUVB and BBIO convertible note offerings bullish long-term and shareholder aligned.+9.9%
2026-06-26@Biotech2k1+0.45Lists core portfolio names by category and plans 70% cash before bubble pops, capped to six.+9.9%
2026-06-25@Biotech2k1+0.45Lists selected top holdings from deep dives, capped to first six tickers.+10.8%
2026-06-23@OzmosiHealth+0.20BridgeBio will present Phase 3 achondroplasia results on 2026-06-28.+12.5%
2026-06-22@Quantumup1+0.00Oppenheimer assumes BBOT coverage with Outperform and $22 PT.+12.0%
2026-06-22@semodough+0.35BBIO positive PROPEL 3 data will be shared as a late-breaking presentation June 27-30, 2026.+12.0%
2026-06-22@OzmosiHealth+0.10BridgeBio plans to present Phase 3 PROPEL 3 primary results.+12.0%
2026-06-22@PrismMarketView+0.45BridgeBio Phase 3 PROPEL 3 showed strong growth data for oral achondroplasia drug.+12.0%

“Since then” = price move from the close on the signal's date (PT) to the latest close — what happened after they said it, not a backtest. A — means no trading session has closed since the signal yet. Sentiment is our extracted per-tweet score, −1…+1.